Global Early Toxicity Testing Market is Expected to Reach $1,301 Million by 2025

According to a new report published by KD Market Insights, titled, "Early toxicity testing Market by Technique and End User: Global Opportunity Analysis and Industry Forecast, 2018 - 2025," the early toxicity testing market accounted for $739 million in 2017 is expected to reach $1,301 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.

Early toxicity testing is analysis of new molecular entity during development process to obtain data related to the toxic effects of compound on body. Testing is performed to analyze the different type of unwanted effects produced by the compound in the body. These severe adverse drug reactions in the body can be circumvented with the use of early toxicity testing which makes it an important part of preclinical testing. The testing is carried out in different mediums such as in vivo, in vitro, and in silico. These tests are carried out before clinical trials to analyze the drug candidates, which are further tested in clinical studies carried out in humans.

Factors that drive the growth of the market include rise in R&D activities and surge in stringent regulatory authorities concerning public healthcare welfare. Increase in adoption of in vitro model which is the major current early toxicity testing market trend also boosts the growth of the market. However, challenges of preclinical testing hamper the market growth. Furthermore, technological advancements in preclinical diagnostic equipment provide lucrative opportunities for the early toxicity testing market growth.

Request for Sample @ : www.kdmarketinsights.com/sample/5266

On the basis of technique, the in vitro segment is a major revenue contributor in 2017 and is expected to maintain its dominant position throughout the analysis period due to rise in adoption of this technique across different diagnostic areas. Governments of different countries such as the U.S., the UK, Germany, and others are extensively active toward protection of animals. These countries have banned testing of cosmetic and household products on animals. Therefore, in vitro testing serves as a feasible alternative to in vivo testing, which also fuels the growth of the in vitro market. The in silico segment is expected to be the fastest growing segment during the forecast period, owing to rise in its adoption due to advantages offered by the technique such as determination of metabolic pathways of active molecules.

According to end users, the pharmaceutical industry segment accounted for the highest early toxicity testing market share in 2017, and is anticipated to maintain this trend over the forecast period, owing to rise in number of clinical trials for drug development. Cosmetics industry segment is the fastest growing segment during the forecast period owing to the stringent government regulations monitoring the assessment of chemicals incorporated in cosmetic products.

In 2017, Europe accounted for one-third of the total early toxicity testing market size and is expected to continue this trend owing to higher number of R&D activities, presence of research lab, companies and institutes, and wide availability of technologically advanced preclinical diagnostic instruments. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period.

Key Findings of the Early Toxicity Testing Market:

- Pharmaceutical industry occupied two-thirds share of the market in 2017.

- The in silico segment is anticipated to grow with the highest CAGR throughout the forecast period.

- The in vitro segment accounted for half the share of the global early toxicity testing market in 2017.

- The cosmetic segment is anticipated to grow at the highest rate during the analysis period.

The major companies profiled in this report include Agilent Technologies, Inc., General Electric Company (GE Healthcare), Danaher Corporation (Beckman Coulter, Inc.), Evotec AG (Cyprotex), Bioanalytical Systems, Inc., Bruker Corporation, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.), and Myriad Genetics, Inc. (Myriad RBM).

Browse Full Report & TOC: https://www.kdmarketinsights.com/product/early-toxicity-testing-market-amr

Contact Us

150 State Street, 3rd Floor,
Albany, New York
United States (12207)
Telephone: +1-518-300-1215
Email: - sales@kdmarketinsights.com
Website: - www.kdmarketinsights.com

About Us:

KD Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.

Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (upto 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision. Our clients list includes various Fortune 500 companies and leading advisory firms.

This release was published on openPR.